Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target< (This gene does not contain this module)

Gene: NR4A1

Summary for NR4A1

Gene information	Gene symbol	NR4A1
	Ensembl ID	ENSG00000123358
	Entrez ID	3164
	Gene name	nuclear receptor subfamily 4 group A member 1
	Synonyms	GFRP1\|HMR\|N10\|NAK-1\|NGFIB\|NUR77\|TR3
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: NR4A1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.262872	7.24e-30
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.394644	5.09e-19
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.44833	2.66e-14
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.268631	2.91e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.425995	6.66e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.899286	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.347295	2.57e-02
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.481799	1.24e-09
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.414319	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.492762	8.23e-18
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.467579	4.15e-41
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.383003	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.26058	2.44e-09
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.379113	7.78e-19
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.792739	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.19563	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.417283	8.68e-23
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.76794	1.41e-19
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.769365	2.98e-22
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	1.9144	6.88e-06
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	1.19566	2.28e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.823646	1.33e-19
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.19004	1.33e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.599515	1.27e-31
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.308206	5.22e-11
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.573022	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.485071	5.78e-11
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.338635	3.56e-14
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.483516	9.19e-42
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	0.415243	2.65e-15
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	0.594355	9.25e-22
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.545473	2.23e-25
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	1.08444	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.492766	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.386779	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.17424	0.00e+00

Top

Expression of NR4A1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to NR4A1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating NR4A1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
NR4A1	hsa-miR-656-3p	95.1742	NM_002135
NR4A1	hsa-miR-4719	92.623	NM_002135
NR4A1	hsa-miR-4651	92.4957	NM_001202233
NR4A1	hsa-miR-608	92.4957	NM_001202233
NR4A1	hsa-miR-4801	90.7678	NM_002135
NR4A1	hsa-miR-3190-3p	89.7957	NM_001202233
NR4A1	hsa-miR-1277-5p	89.4672	NM_002135
NR4A1	hsa-miR-3152-3p	88.4737	NM_001202233
NR4A1	hsa-miR-200a-5p	88.308	NM_002135
NR4A1	hsa-miR-200b-5p	88.308	NM_002135
NR4A1	hsa-miR-4731-3p	87.3682	NM_002135
NR4A1	hsa-miR-124-3p	86.3826	NM_002135
NR4A1	hsa-miR-506-3p	86.3826	NM_002135
NR4A1	hsa-miR-4666a-5p	82.7996	NM_001202233
NR4A1	hsa-miR-215-3p	81.612	NM_002135
NR4A1	hsa-miR-4533	81.1691	NM_001202233
NR4A1	hsa-miR-12129	80.8453	NM_001202233
NR4A1	hsa-miR-4778-3p	80.6869	NM_002135

Page: 1

Top

Motifs and transcription factors (TFs) regulating NR4A1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
NR4A1	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
NR4A1	metacluster_29.6	ZNF436 (directAnnotation).
NR4A1	yetfasco__TBP-TFIIA-TFIIB_1330	GTF2B; TBPL2 (inferredBy_Orthology).
NR4A1	transfac_pro__M05985	ZNF394 (inferredBy_Orthology).
NR4A1	metacluster_190.8	ILF2; NFAT5; NFAT5; NFAT5; NFAT5; NFATC1; NFATC2; NFATC3; NFATC4; NFATC4 (directAnnotation).
NR4A1	metacluster_130.2	ZNF182; ZNF22; ZNF225; ZNF225; ZNF285; ZNF362; ZNF362; ZNF384; ZNF487; ZNF512; ZNF570; ZNF613 (directAnnotation). ZNF384 (inferredBy_Orthology).
NR4A1	transfac_pro__M06499	ZNF383 (directAnnotation).
NR4A1	transfac_pro__M05352	ZNF692 (inferredBy_Orthology).
NR4A1	transfac_pro__M05419	ZBTB45 (directAnnotation).
NR4A1	transfac_pro__M05935	ZNF382 (directAnnotation).
NR4A1	tfdimers__MD00515	ARID3A; KLF4 (directAnnotation).
NR4A1	tfdimers__MD00158	DBP; ZNF354C (directAnnotation).
NR4A1	transfac_pro__M01665	IRF8 (directAnnotation).
NR4A1	hdpi__RAB18	RAB18 (directAnnotation).
NR4A1	metacluster_38.2	STAT3 (inferredBy_Orthology).
NR4A1	transfac_pro__M06830	ZNF528 (directAnnotation).
NR4A1	transfac_pro__M06253	ZSCAN2 (inferredBy_Orthology).
NR4A1	transfac_pro__M05387	ZNF653 (inferredBy_Orthology).
NR4A1	transfac_pro__M01250	E2F1 (directAnnotation).
NR4A1	transfac_pro__M06877	ZNF224 (directAnnotation).
NR4A1	transfac_pro__M05539	OSR2 (inferredBy_Orthology).
NR4A1	transfac_pro__M06391	ZNF836 (directAnnotation).
NR4A1	transfac_pro__M05755	ZNF718 (directAnnotation).
NR4A1	kznf__ZSCAN29_TF_Evolution_PBM	ZSCAN29 (directAnnotation).
NR4A1	transfac_pro__M01886	NFATC3 (directAnnotation).
NR4A1	metacluster_137.2	ATF3; BACH2; BATF; BATF; BATF; BATF; BATF3; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSB; FOSB; FOSB; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; INSM2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMARCC1 (directAnnotation). ATF3; ATF3; BATF; FOS; FOSB; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUND; JUND; JUND; JUND (inferredBy_Orthology).
NR4A1	transfac_pro__M01861	ATF1 (directAnnotation).
NR4A1	transfac_pro__M06700	ZNF71 (directAnnotation).
NR4A1	metacluster_111.5	E4F1; E4F1 (directAnnotation).
NR4A1	transfac_pro__M06776	ZNF214 (directAnnotation).
NR4A1	dbtfbs__E4F1_K562_ENCSR731LHZ_merged_N1	E4F1 (directAnnotation).
NR4A1	taipale_cyt_meth__CREB1_NRTGAYGCGTN_eDBD_meth_repr	CREB1 (directAnnotation).
NR4A1	transfac_pro__M05707	ZNF239 (inferredBy_Orthology).
NR4A1	transfac_pro__M05574	ZFP92 (directAnnotation).
NR4A1	taipale_cyt_meth__HSF5_AACRTTCTAGAAYGYT_eDBD_meth	HSF5 (directAnnotation).
NR4A1	tfdimers__MD00036	FOS; FOSB; FOSL1; FOSL2; ILF2; JUN; JUNB; JUND; NFATC2 (directAnnotation).
NR4A1	transfac_pro__M01251	E2F1 (directAnnotation).
NR4A1	metacluster_144.8	ZNF30; ZNF30 (directAnnotation).
NR4A1	jaspar__MA1708.1	ETV7 (directAnnotation).
NR4A1	taipale_tf_pairs__ETV2_FOXO6_RCCGGATGTTKWN_CAP	ETV2; FOXO6 (directAnnotation).
NR4A1	swissregulon__hs__ETV6	ETV6 (directAnnotation).
NR4A1	taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr	ERF; FOXI1 (directAnnotation).
NR4A1	transfac_pro__M06173	ZNF85 (directAnnotation).
NR4A1	kznf__ZNF571_Imbeault2017_OM_RCADE	ZNF571 (directAnnotation).
NR4A1	metacluster_23.5	WT1 (directAnnotation).
NR4A1	transfac_pro__M05481	ZNF202 (directAnnotation).
NR4A1	swissregulon__hs__SOX9	SOX9 (directAnnotation).
NR4A1	metacluster_156.4	NFIL3 (directAnnotation). NFIL3 (inferredBy_Orthology).
NR4A1	metacluster_70.14	POU2F3 (directAnnotation).
NR4A1	metacluster_160.7	ZSCAN21 (directAnnotation).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
NR4A1	hdpi__NR4A1	down	Malignant cells	GSE150930	NA
NR4A1	transfac_pro__M04622	down	CD8+ T cells	GSE207422_Tor	post
NR4A1	taipale_cyt_meth__NR4A1_NAAAGGTCAN_eDBD_1	up	Plasma cells	GSE207422_Tor	post

Page: 1

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."